FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
FDA rejects Summit's ivonescimab, halting the first PD-1xVEGF bispecific antibody from reaching the US market.
Evidence dossier
Intelligence passport
Measured timeline
-
Detected
-
Peak measured velocity
-
Evidence threshold reached
-
Latest coverage observed
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
What happened
- Velocity & Diffusion: Coverage exploded across 8 distinct news outlets with 8 published articles, achieving a live velocity of 6.
- Primary Driver: FDA rejects Summit's ivonescimab, halting the first PD-1xVEGF bispecific antibody from reaching the US market.
- Predictive Outlook: Archynetys algorithmic models forecast this story will fade from trending status over the next 24 hours.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
The US Food and Drug Administration declined to approve ivonescimab, a bispecific antibody targeting PD-1 and VEGF developed by China's Akeso and licensed to Summit Therapeutics, for a narrow lung cancer indication. Summit disclosed the complete response letter in a regulatory filing, stating the agency determined the HARMONi-2 trial missed its key overall survival endpoint in the intended population.
Reuters and STAT confirm the rejection centered on the trial's failure to demonstrate a statistically significant survival benefit, while Endpoints News notes the decision applies specifically to the narrow setting studied. Financial Times frames the move as a setback for Beijing's biotech ambitions, marking the first major Chinese-invented oncology asset to face a US regulatory denial at this stage. Bloomberg and Fierce Pharma emphasize the broader implication: the PD-1xVEGF class, widely viewed as a potential successor to Keytruda combinations, now lacks a clear US pathway.
Summit said it will request a meeting with the FDA to discuss next steps, but no timeline for resubmission or additional trials has been announced. Akeso's China approval for the same asset remains unaffected.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. Updated 7h ago.
Who reported it (8)
-
F.D.A. Rejects Closely Watched Lung Cancer Drug From ChinaThe New York Times · 12h ago
-
FDA rejects cancer drug invented in China in blow to Beijing’s biotech sectorFinancial Times · 12h ago
-
US FDA Rejects Summit’s China-Originated Lung Cancer DrugBloomberg.com · 12h ago
-
FDA rejects Summit, Akeso’s ivonescimab in narrow lung cancer settingEndpoints News · 12h ago
-
Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License ApplicationYahoo Finance · 12h ago
-
-
-
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF classFierce Pharma · 12h ago
Questions people are asking
What is ivonescimab?
A bispecific antibody that targets both PD-1 and VEGF, developed by Akeso and licensed to Summit Therapeutics for ex-China rights.
Why did the FDA reject it?
The HARMONi-2 trial did not meet its primary overall survival endpoint in the studied lung cancer population.
Does this affect its status in China?
No, Akeso's approval in China is unchanged.
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
Topics
From around our network
Related trends
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
The FDA has ordered new warning labels on blockbuster GLP-1 drugs Ozempic and Zepbound over a rare eye condition linked to sudden blindness, shaking confidence in the red-hot weight-loss market.
‘I’m destroyed.’ Owner speaks on E. coli outbreak that shut down SLO County farm
Brookshire Farms faces shutdown after an E. coli outbreak sickens fifteen, including three children with kidney failure, and co‑owner declares 'I'm destroyed'.
DEA And Marijuana Rescheduling Opponents File Final Briefs In Hearing Ahead Of Judge's Decision
Judge's decision looms on marijuana rescheduling as opponents file final briefs.
Breakthrough: FDA Approves First Drug Offering a 'Functional Cure' For Chronic Hepatitis B
The FDA approved Hibsago, the first drug offering a functional cure for chronic hepatitis B, after clinical trials showed 19% of patients achieved undetectable virus levels that persisted after treatment ended.
Are we approaching a new era of Alzheimer’s prevention?
New FDA-approved blood tests and anti-amyloid drugs are sparking debate over whether Alzheimer's can now be prevented before symptoms appear.
Exclusive | AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
AstraZeneca reportedly made a $10 billion bid for Rhythm Pharmaceuticals, sparking speculation about a potential bidding war.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.